U.K. Public Spending Panel Urges More Clinical Data Access, Sharing
This article was originally published in The Pink Sheet Daily
Executive Summary
Influential U.K. parliamentary panel keeps the pressure up on making clinical trial data more widely available, including greater sharing between regulators and health technology assessors.
You may also be interested in...
Clinical Trials Transparency: EMA Delay Gives Industry Initiative More Time To Take Root
EMA’s plans for access to clinical trials data not set to be ready until well into 2014.
GSK Champions More Trial Data Disclosure, But PhRMA Objects
In its latest move on the transparency front, Glaxo endorses the U.K.-driven AllTrials campaign, which calls for releasing all clinical trial results. Announcement runs counter to PhRMA’s defense against requirements for more disclosure.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.